ATE228373T1 - Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung - Google Patents

Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung

Info

Publication number
ATE228373T1
ATE228373T1 AT93907044T AT93907044T ATE228373T1 AT E228373 T1 ATE228373 T1 AT E228373T1 AT 93907044 T AT93907044 T AT 93907044T AT 93907044 T AT93907044 T AT 93907044T AT E228373 T1 ATE228373 T1 AT E228373T1
Authority
AT
Austria
Prior art keywords
antigens
suppression
waiting
autoimmune diseases
autoantigens
Prior art date
Application number
AT93907044T
Other languages
English (en)
Inventor
Howard L Weiner
Ariel Miller
Zhengri Zhang
Ahmad Al-Sabbagh
David A Hafler
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Application granted granted Critical
Publication of ATE228373T1 publication Critical patent/ATE228373T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93907044T 1992-02-28 1993-02-25 Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung ATE228373T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84375292A 1992-02-28 1992-02-28
PCT/US1993/001705 WO1993016724A1 (en) 1992-02-28 1993-02-25 Bystander suppression of autoimmune diseases

Publications (1)

Publication Number Publication Date
ATE228373T1 true ATE228373T1 (de) 2002-12-15

Family

ID=25290916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907044T ATE228373T1 (de) 1992-02-28 1993-02-25 Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung

Country Status (16)

Country Link
US (1) US20050208061A1 (de)
EP (1) EP0627933B1 (de)
JP (1) JP3712260B2 (de)
KR (1) KR950700082A (de)
AT (1) ATE228373T1 (de)
AU (2) AU3778593A (de)
BR (1) BR9306042A (de)
CA (1) CA2117492C (de)
DE (1) DE69332518T2 (de)
DK (1) DK0627933T3 (de)
ES (1) ES2190784T3 (de)
HU (1) HU220357B (de)
IL (1) IL104880A (de)
NO (1) NO319062B1 (de)
PT (1) PT627933E (de)
WO (1) WO1993016724A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
EP0752879A4 (de) * 1994-04-08 1999-07-21 Brigham & Womens Hospital Behandlung von autoimmun-krankheiten mittels oraler tolerierung und/oder th2-erhöhenden cytokinen
EP0752880A4 (de) * 1994-04-08 2000-08-09 Brigham & Womens Hospital Behandlung von autoimmunkrankheiten mittels orales tolerierung und/oder interferon vom type i
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
WO1997046253A2 (en) * 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease
HUP0001960A2 (hu) * 1997-01-24 2000-10-28 Autoimmune, Inc. Metotrexát kombináció autoimmun tünetek befolyásolására
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
CA2328108A1 (en) * 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
AU6481301A (en) * 2000-05-24 2001-12-03 Us Health Methods for preventing strokes by inducing tolerance to e-selectin
EP1842551A1 (de) * 2000-05-24 2007-10-10 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services E-selectin zur behandlung oder vorbeugung von schlaganfall
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2113560A1 (de) * 2008-04-28 2009-11-04 TXCell Zusammensetzungen zur Behandlung eines Arthritisleidens
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2012049312A1 (en) * 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
BR112013009068A2 (pt) * 2010-10-15 2016-07-19 Alk Abelló As supressão de uma resposta imune de hipersensibilidade com antígeno não relacionado derivado de material fonte de alérgeno
KR102283760B1 (ko) 2012-06-21 2021-08-03 노쓰웨스턴유니버시티 펩티드 접합된 입자
EP2928500B1 (de) 2012-12-04 2019-03-06 Phosphorex Inc. Mikropartikel und nanopartikeln mit negativen oberflächenladungen
CA3261641A1 (en) 2013-03-13 2025-06-12 Oncour Pharma, Inc. Immune-modifying particles for the treatment of inflammation
RS59801B2 (sr) 2013-08-13 2024-03-29 Univ Northwestern Čestice konjugovane peptidom
KR102822161B1 (ko) 2015-12-23 2025-06-18 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 공유결합 중합체-항원 접합 입자
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
TW202544024A (zh) 2024-03-18 2025-11-16 美商庫爾製藥發展公司股份有限公司 用於抗原特異性耐受性之sting促效劑

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985436A (en) * 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
CA1302880C (en) * 1986-07-25 1992-06-09 Peter Koepff Agents for the treatment of arthroses
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
ES2144398T3 (es) * 1989-12-20 2000-06-16 Autoimmune Inc Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
US5075112A (en) * 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
AU651097B2 (en) * 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL99754A (en) * 1990-10-15 1996-08-04 Autoimmune Inc Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis

Also Published As

Publication number Publication date
IL104880A0 (en) 1993-06-10
CA2117492C (en) 2009-04-07
DK0627933T3 (da) 2003-03-24
HU9402468D0 (en) 1994-10-28
ES2190784T3 (es) 2003-08-16
EP0627933A1 (de) 1994-12-14
AU3754297A (en) 1997-11-20
NO943151D0 (no) 1994-08-25
EP0627933A4 (de) 1997-01-15
HUT74832A (en) 1997-02-28
KR950700082A (ko) 1995-01-16
US20050208061A1 (en) 2005-09-22
AU720695B2 (en) 2000-06-08
DE69332518D1 (de) 2003-01-09
IL104880A (en) 1997-07-13
NO943151L (no) 1994-10-26
BR9306042A (pt) 1997-11-18
DE69332518T2 (de) 2003-09-04
PT627933E (pt) 2003-04-30
EP0627933B1 (de) 2002-11-27
JP3712260B2 (ja) 2005-11-02
HU220357B (hu) 2001-12-28
JPH08504745A (ja) 1996-05-21
WO1993016724A1 (en) 1993-09-02
NO319062B1 (no) 2005-06-13
CA2117492A1 (en) 1993-09-02
AU3778593A (en) 1993-09-13

Similar Documents

Publication Publication Date Title
ATE228373T1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
NO931372D0 (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
DE3854741D1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
ES2065303T5 (es) Procedimiento de diagnosis y vacuna especifica.
FR2620941B1 (fr) Vaccin contenant des adjuvants et des antigenes tumoraux
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
NO964200L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
DK0536302T3 (da) Forbedrede adjuvanser og vacciner
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
MX9603124A (es) Vacuna contra el virus de la enfermedad de newcastle benigna.
BR9808878A (pt) Imunização contra moléculas endógenas
CS578887A1 (en) Inactivated antigen of cattle's mucosal disease's virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0627933

Country of ref document: EP

REN Ceased due to non-payment of the annual fee